TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05200559
Drug: E7777
Normalized name: Elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
Study: NCT05962255
Drug: Furosemide intravenous infusion
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics.
Study: NCT05962255
Drug: Continous intravenous infusion of 0.9% Sodium Chloride solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
Study: NCT05376722
Drug: pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pamiparib 40 mg orally, twice a day
Study: NCT05376722
Drug: abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biraterone acetate 1000 mg orally, once a day
Study: NCT05376722
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone acetate tablets (prednisone) 5 mg, once a day
Study: NCT05414175
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06613880
Drug: standard IST combined with Romiplostim N01
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.
Study: NCT06614036
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
Study: NCT06614036
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
Study: NCT04761198
Drug: Etigilimab
Normalized name: Etigilimab
DrugBank: Etigilimab (DB18854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of IV etigilimab every 2 weeks
Study: NCT04761198
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion of nivolumab every 2 weeks
Study: NCT06717464
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg intravenous injection, q3w, for 54 weeks (18 cycles)
Study: NCT06714838
Drug: Rituximab (Mabthera)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered in a hospital setting in the course of one day. It will be given intravenously, at time points baseline, week 2 and week 26.
Study: NCT05393245
Drug: Tiotropium+Olodaterol
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium+Olodaterol
Study: NCT05823896
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300/100 mg tablet twice daily (q12h) administered orally for 15 days
Study: NCT05823896
Drug: Placebo/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg tablet twice daily (q12h) administered orally for 15 days
Study: NCT05821452
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mgQ3w
Study: NCT05821452
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175mg/m2，D1，Q3w
Study: NCT05821452
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2，D1，Q3w
Study: NCT03924492
Drug: ZULRESSO (brexanolone) injection
Normalized name: Zulresso
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZULRESSO
Study: NCT05542446
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection.
Study: NCT04762082
Drug: Tadalafil 10 MG
Normalized name: tadalafil 10 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
Study: NCT04963816
Drug: Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
Study: NCT04963816
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine will be given to all groups locally with QLB
Study: NCT04963816
Drug: Dexamethasone Phosphate 4 MG/ML Injectable Solution locally
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
Study: NCT04753489
Drug: Rivaroxaban film-coated tablet 10 mg
Normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
Study: NCT05833711
Drug: Froniglutide
Normalized name: Froniglutide
DrugBank: Froniglutide (DB16178)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Weekly Injection
Study: NCT00002143
Drug: Acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04418895
Drug: fluoropyrimidine +/- oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
Study: NCT05200312
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg capsules administered by mouth twice daily (21-day cycles).
Study: NCT05200312
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
Study: NCT05200312
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT05200312
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT05200312
Drug: Prednisone (or equivalent)
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Study: NCT05979961
Drug: gemcitabine and cisplatin (Induction chemotherapy)
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
Study: NCT05187260
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SPINRAZA® (nusinersen) prescribed as part of standard of care
Study: NCT04800393
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
Study: NCT04800393
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol-based total intravenous anesthesia during breast cancer surgery
Study: NCT04991493
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured.
Study: NCT04924621
Drug: Midazolam(T group)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 0.05mg/kg, intravenous injection
Study: NCT04924621
Drug: Propofol(T group)
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 2-3ug/ml, intravenous injection
Study: NCT04924621
Drug: Rocuronium(T group)
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium 0.06mg/kg, intravenous injection
Study: NCT04924621
Drug: Midazolam(C group)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 0.05mg/kg, intravenous injection
Study: NCT04924621
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1-2ug/ml, intravenous injection
Study: NCT04924621
Drug: Tetracaine(C group)
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml tetracaine was injected with cyclothyroid membrane puncture.
Study: NCT05073939
Drug: Oral Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of oxytocin (24 international units) orally
Study: NCT06003777
Drug: PF-06954522
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
Study: NCT05836272
Drug: Norepinephrine Bitartrate
Normalized name: Norepinephrine Bitartrate
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion.
Study: NCT00893854
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05698303
Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
Study: NCT05195203
Drug: HS-10353
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose(s) of HS-10353
Study: NCT04883255
Drug: 10 mg Δ9-tetrahydrocannabinol (THC)
Normalized name: Δ9-tetrahydrocannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of orally-administered THC (dronabinol), 10 mg
Study: NCT04883255
Drug: 600 mg cannabidiol (CBD)
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-day course of orally-administered CBD, 600 mg
Study: NCT05922930
Drug: TROP2-CAR-NK
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IP (intraperitoneal)
Study: NCT05922930
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT04892186
Drug: Myo-inositol
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference.
Study: NCT06438679
Drug: Tofacitinib 5 MG
Normalized name: tofacitinib 5 MG
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib 5mg BID+thalidomide 50mg BID+tacrolimus 0.1mg/kg QD per oral
Study: NCT04892186
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference.
Study: NCT06717490
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In patients allocated to the MS group, a fixed dose of magnesium sulfate diluted in a fixed volume of natural saline will be administered intravenously.~Thromboelastometry will be performed pre and post magnesium administration.
Study: NCT06717529
Drug: Methylprednisolone Acetate Injection
Normalized name: methylprednisolone acetate Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive 2mL of methylprednisolone acetate solution containing 80 mg of the medicine in other knee joint.
Study: NCT06714695
Drug: Chitosan
Normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chitosan mouthwash
Study: NCT06716801
Drug: Cenobamate
Normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adult patients affected by epilepsy with focal-onset seizures with or without secondary generalization who have not been adequately controlled despite a history of treatment with 2 or 3 anti-seizure medications.
Study: NCT06717113
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to the examination, patients will be required to fast for at least 6 hours. 18F-FDG (0.05-0.1 mCi/kg) will be intravenously injected, and one hour after the injection, head and torso imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the upper third of the thigh. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
Study: NCT06717113
Drug: 68Ga-BC1
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient. Two hours after the injection, whole-body imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the mid-thigh. If any indeterminate lesions are found during the routine imaging, delayed imaging will be performed for further differentiation. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
Study: NCT06715449
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day in addition to their usual stroke care.
Study: NCT06717945
Drug: remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
Study: NCT06717945
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
Study: NCT06472037
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg，IV，D1，Q3W
Study: NCT06472037
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2，IV，D1、D8、D15，Q4W
Study: NCT06472037
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m2，IV，D1、D8、D15，Q4W
Study: NCT02772081
Drug: Curosurf through conventional administration (endotracheal tube)
Normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
Study: NCT05617118
Drug: Baclofen 10mg
Normalized name: BACLOFEN 10MG TAB
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
Study: NCT05617118
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
Study: NCT06349824
Drug: injection Dextrose water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextrose will be injected around median nerve in wrist
Study: NCT05083078
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered subcutaneously.
Study: NCT05083078
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab will be administered subcutaneously.
Study: NCT04658927
Drug: Dexamethasone, 0.4mg
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iLUX + dextenza
Study: NCT04658927
Drug: Prednisone acetate
Normalized name: Prednisone acetate
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% and iLux
Study: NCT05357833
Drug: Ferumoxytol infusion
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
Study: NCT05357833
Drug: Gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
Study: NCT05245539
Drug: CVL-231
Normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.